Ototoxicity of cisplatin

Ivanov S.A.; Zhuravskiĭ S.G.; Galagudza M.M.

doi:https://doi.org/

Close metadata

Abstract:

The objective of this publication is to summarize "classical" and modern concepts of pathogenesis, clinical features of cisplatin ototoxicity, its screening, and prophylaxis. It is argued that pathogenesis of a cisplatin-induced injury to the inner ear shares common features with the ototoxic mechanisms of action of other pharmaceuticals even though it is characterized by certain important differences. The authors consider the mechanisms of ototropicity, specific cytochemical aspects of cisplatin cytotoxicity that aggravate risk factors, and genetic predisposition to the development of iatrogenic problems. The data are presented on monitoring and experimental aspects of otoprotection for the prevention of cisplatin-induced damage to the auditory analyzer.

Keywords:

cisplatin

cisplatin ototoxicity

cisplatin ototropicity

otoprtotection

Authors:

Ivanov S.A.

A.F. Tsyba Medical Radiological Research Centre — Branch of the National Medical Research Center of Radiology of the Ministry of Healthcare of the Russia, Obninsk, Russia

Zhuravskiĭ S.G.

Laboratoriia slukha i rechi NITs, kafedra patofiziologii Sankt-Peterburgskogo gosudarstvennogo meditsinskogo universiteta im. akad. I.P. Pavlova

Galagudza M.M.

Laboratoriia slukha i rechi NITs, kafedra patofiziologii Sankt-Peterburgskogo gosudarstvennogo meditsinskogo universiteta im. akad. I.P. Pavlova;
NIL metabolizma miokarda Federal'nogo tsentra serdtsa, krovi i éndokrinologii im. V.A. Almazova, Sankt-Peterburg

Close metadata

References:

Zarandy M.M., Rutka J. Diseases of the Inner Ear. Springer-Verlag Berlin Heidelberg 2010; 85-89.
Roland P.S., John A., Rutka M.D. Ototoxicity. BC Decker, ON 2004; 50-75.
Fuertes M.A., Castilla J., Alonso C. et al. Novel concepts in the development of platinum antitumor drugs. Curr Med Chem Anti-Cancer Agents 2002; 2: 539-551.
Ramírez-Camacho R., Fernández D.E., Verdaguer J.M. et al. Cisplatin-induced hearing loss does not correlate with intracellular platinum concentration. Acta Otolaryngol 2008; 128: 5: 505-509.
Van Ruijven M.W., de Groot J.C., Klis S.F. et al. The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study. Hear Res 2005; 205: 1-2: 241-248.
Vinnikov Ya.A., Titova L.K. Kortiev organ. Gistofiziologiya i gistokhimiya. M: Izd-vo AN SSSR 1961.
Mitrofanov V.V. Patogeneticheskie mekhanizmy formirovaniya patologii ushnogo labirinta pri deistvii proizvodstvennykh fizicheskikh faktorov: Avtoref. dis. ... d-ra med. nauk. SPb 2002.
Pokotilenko A.K. Morfologicheskaya kharakteristika i patogenez izmenenii vnutrennego ukha pri gipertonicheskoi bolezni: Avtoref. dis. … d-ra med. nauk. Kiev 1967.
Liang F., Schulte B.A., Qu C. Inhibition of the calcium- and voltage-dependent big conductance potassium channel ameliorates cisplatin-induced apoptosis in spiral ligament fibrocytes of the cochlea. Neuroscience 2005; 135: 263-271.
Chung W.H., Boo S.H., Chung M.K. et al. Proapoptotic effects of NF-kappa B on cisplatin-induced cell death in auditory cell line. Acta Otolaryngol 2008; 128: 10: 1063-1070.
Riedemann L., Lanvers C., Deuster D. et al. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J 2008; 8: 1: 23-28.
Schweitzer V.G., Rarey K.E., Dolan D.F. et al. Ototoxicity of cisplatin vs. platinum analogs CBDCA (JM-8) and CHIP (JM-9). Otolaryngol Head Neck Surg 1986; 94: 4: 458-470.
Zheng J., Dai C., Steyger P.S. et al. Vanilloid receptors in hearing: altered cochlear sensitivity by vanilloids and expression of TRPV1 in the organ of corti. J Neurophysiol 2003; 90: 1: 444-455.
Mukherjea D., Jajoo S., Whitworth C. et al. Short interfering RNA against transient receptor potential vanilloid 1 attenuates cisplatin-induced hearing loss in the rat. J Neurosci 2008; 28: 13056-13065.
Mukherjea D., Jajoo S., Kaur T. et al. Transtympanic administration of short interfering (si)RNA for the NOX3 isoform of NADPH oxidase protects against cisplatin-induced hearing loss in the rat. Antioxid Redox Signal 2010; 13: 5: 589-598.
Chung W.H., Boo S.H., Chung M.K. et al. Proapoptotic effects of NF-kappa B on cisplatin-induced cell death in auditory cell line. Acta Otolaryngol 2008; 10: 1063-1070.
Rybak L.P., Mukherjea D., Jajoo S., Ramkumar V. Cisplatin Ototoxicity and Protection: Clinical and Experimental Studies Tohoku. J Exp Med 2009; 219: 3: 177-186.
Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 47: 7265-7279.
Felix D., Oestreicher E. (eds). Rational Pharmacotherapy of the Inner Ear. Adv Otorhinolaryngol. Basel Karger 2002; 59: 96-105.
Mandic A., Hansson J., Linder S., Shoshan M.C. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 2003; 278: 11: 9100-9106.
So H.S., Park C., Kim H.J. et al. Protective effect of T-type calcium channel blocker flunarizine on cisplatin-induced death of auditory cells. Hear Res 2005; 204: 1-2: 127-139.
Sha S.H., Taylor R., Forge A., Schacht J. Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals. Hear Res 2001; 155: 1-2: 1-8.
Lambeth J.D. Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic Biol Med 2007; 43: 3: 332-347.
McFadden S.L., Ding D., Salvemini D., Salvi R.J. M40403, a superoxide dismutase mimetic, protects cochlear hair cells from gentamicin, but not cisplatin toxicity. Toxicol Appl Pharmacol 2003; 186: 1: 46-54.
Bokemeyer C., Berger C.C., Hartmann J.T. et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998; 77: 8: 1355-1362.
De Jongh F.E., Van Veen R.N., Veltman S.J. et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 2003; 88: 8: 1199-1206.
Simon T., Hero B., Dupuis W. et al. The incidence of hearing impairment after successful treatment of neuroblastoma. Klin Padiat 2002; 214: 4: 149-152.
Coradini P.P., Cigana L., Selistre S.G. et al. Ototoxicity from cisplatin therapy in childhood cancer. J Pediat Hematol Oncol 2007; 29: 6: 355-360.
Kushner B., Budnick A., Kramer K. et al. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 2006; 107: 2: 417-422.
Bertolini P., Lassalle M., Mercier G. et al. Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss. J Pediat Hematol Oncol 2004; 26: 10: 649-655.
Safirstein R., Daye M., Guttenplan J. Mutagenic activity and identification of excreted platinum in human and rat urine and rat plasma after administration of cisplatin. Cancer Lett 1983; 18: 329.
Mount R.J., Takeno S., Wake M., Harrison R.V. Carboplatin ototoxicity in the chinchilla: lesions of the vestibular sensory epithelium. Acta Otolaryngol Suppl 1995; 519: 60-65.
Zhuravskii S.G., Setkhiyaasiilan T., Degtyareva Yu.A. Patogeneticheskaya geterogennost' ototoksicheskikh oslozhnenii, vyzyvaemykh aminoglikozidnymi antibiotikami. Vestn otorinolar 2005; 1: 45-47.
Moiseev A.A., Khrunin A.V., Pavlyushina E.M. Polimorfizm genov glutation-S-transferaz i rezul'taty khimioterapii raka yaichnika. M: Izd-vo RONTs im. N.N. Blokhina 2008; 19-21.
Oldenburg J., Kraggerud S.M., Cvancarova M. et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007; 25: 6: 708-714.
Peters U., Preisler-Adams S., Hebeisen A. et al. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs 2000; 11: 8: 639-643.
Peters U., Preisler-Adams S., Lanvers-Kaminsky C. et al. Sequence variations of mitochondrial DNA and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Res 2003; 23: 1249-1255.
Schweitzer V.G. Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope 1993; 103: 4 Pt 2: 1-52.
Todd N.W., Alvarado C.S., Brewer D.B. Cisplatin in children: hearing loss correlates with iris and skin pigmentation. J Laryngol Otol 1995; 109: 10: 926-929.
Martin H.C., Schmidt C.M., Boos H.J. et al. Cisplatin-induced hearing loss in children in relation to eye color. HNO 2007; 55: 6: 489-496.
Al-Khatib T., Cohen N., Carret A.S., Daniel S. Cisplatinum ototoxicity in children, long-term follow up. Int J Pediat Otorhinolaryngol 2010; 74: 8: 913-919.
Harrison R.V. An animal model of auditory neuropathy. Ear Hear 1998; 19: 5: 355-361.
Sun W.X., Wang A.M., Bao C.F. et al. Effect of cisplatin on apoptosis of spiral ganglion cell and expression of caspase-3 in mouse cochlea. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2010; 26: 3: 324-328.
Bogomil'skii M.R., D'yakonova I.N., Rakhmanova I.V. i dr. Elektrofiziologicheskaya otsenka slukhovoi funktsii posle vvedeniya tsisplatina. Vestn otorinolar 2010; 3: 24-26.
Freitas M.R., Silva V.C., Brito G.A. et al. Distortion-product otoacoustic emissions and auditory brainstem responses sensitivity assessment in cisplatin-induced ototoxicity in rats. Braz J Otorhinolaryngol 2009; 75: 4: 476-484.
Van den Berg J.H., Beijnen J.H., Balm A.J., Schellens J.H. Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treat Rev 2006; 32: 5: 390-397.
Wimmer C., Mees K., Stumpf P. et al. Round window application of D-methionine, sodium thiosulfate, brain-derived neurotrophic factor, and fibroblast growth factor-2 in cisplatin-induced ototoxicity. Otol Neurotol 2004; 25: 33-40.
Li G., Sha S.H., Zotova E. et al. Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action. Lab Invest 2002; 82: 5: 585-596.
Lynch E.D., Gu R., Pierce C., Kil J. Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hear Res 2005; 201: 1-2: 81-89.
Van den Berg J.H., Beijnen J.H., Balm A.J., Schellens J.H. Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treat Rev 2006; 32: 5: 390-397.